Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | chromobox homolog 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | sulfite reductase | 0.018 | 0.5436 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.018 | 0.5436 | 0.4622 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0258 | 0.8644 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0147 | 0.408 | 0.3024 |
Trypanosoma cruzi | p450 reductase, putative | 0.0291 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0111 | 0.2633 | 0.5 |
Brugia malayi | Heterochromatin protein 1 | 0.0084 | 0.1514 | 0.1514 |
Giardia lamblia | Hypothetical protein | 0.0258 | 0.8644 | 0.5 |
Brugia malayi | flavodoxin family protein | 0.0111 | 0.2633 | 0.2633 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0111 | 0.2633 | 0.2633 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0258 | 0.8644 | 0.8644 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0291 | 1 | 1 |
Echinococcus multilocularis | methionine synthase reductase | 0.018 | 0.5436 | 0.4622 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0145 | 0.3989 | 0.5 |
Loa Loa (eye worm) | heterochromatin protein 1 | 0.0084 | 0.1514 | 0.1514 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0291 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0291 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0291 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0111 | 0.2633 | 0.5 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0111 | 0.2633 | 0.2633 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0291 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0145 | 0.3989 | 0.5 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0111 | 0.2633 | 0.2633 |
Leishmania major | cytochrome P450 reductase, putative | 0.0258 | 0.8644 | 0.8159 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0291 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0291 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0291 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0291 | 1 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0258 | 0.8644 | 0.8159 |
Leishmania major | p450 reductase, putative | 0.0291 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.018 | 0.5436 | 0.5436 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0111 | 0.2633 | 0.2633 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0111 | 0.2633 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0291 | 1 | 1 |
Echinococcus granulosus | methionine synthase reductase | 0.018 | 0.5436 | 0.4622 |
Trichomonas vaginalis | chromobox protein, putative | 0.0051 | 0.0147 | 0.0147 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0111 | 0.2633 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0291 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0291 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.018 | 0.5436 | 0.5436 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0145 | 0.3989 | 0.2917 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0291 | 1 | 1 |
Trichomonas vaginalis | chromobox protein, putative | 0.0084 | 0.1514 | 0.1514 |
Treponema pallidum | flavodoxin | 0.0111 | 0.2633 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0291 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0291 | 1 | 1 |
Onchocerca volvulus | Heterochromatin protein 1 homolog | 0.0051 | 0.0147 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0111 | 0.2633 | 0.5 |
Trichomonas vaginalis | chromobox protein, putative | 0.0084 | 0.1514 | 0.1514 |
Loa Loa (eye worm) | hypothetical protein | 0.0291 | 1 | 1 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0111 | 0.2633 | 0.2633 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0291 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0291 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0291 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0291 | 1 | 0.5 |
Trichomonas vaginalis | chromobox protein, putative | 0.0051 | 0.0147 | 0.0147 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.0119 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 37.6505 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase. (Class of assay: confirmatory) [Related pubchem assays: 1379 ] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.